In advance care planning for patients with chronic kidney disease, healthcare professionals are undertrained.

Published Date: 26 Apr 2023

According to a study published online April 17 in the Scandinavian, health care professionals (HCPs) report lacking resources and training to conduct advance care planning (ACP) among patients with chronic kidney disease (CKD).

Read Full News

Latest News

What Caused the Pigmented Spot on Teen Boy's Eye?

Authors discuss how best to diagnose and manage him, given the absence of any symptoms

The HCPFive: Top News for Healthcare Providers from the Week of 01/25 HCPLive Editorial Staff

Stay updated with the latest healthcare breakthroughs, including new phase 2 obesity data, FDA actions, and new hematology guidelines in this week’s essential news roundup.

FDA News Recap: Novel Drug Approvals in First Half of 2026

FDA News Recap: Novel Drug Approvals in First Half of 2026

The HCPFive: Top News for Healthcare Providers from the Week of 04/05

The HCPFive: Top News for Healthcare Providers from the Week of 04/05

Tepezza OBI Achieves Proptosis Reduction in Thyroid Eye Disease in Phase 3 Trial

Tepezza OBI Achieves Proptosis Reduction in Thyroid Eye Disease in Phase 3 Trial

FDA Issues Third Reproxalap CRL for Dry Eye Disease

FDA Issues Third Reproxalap CRL for Dry Eye Disease

Todays Updates

Trappsol Cyclo Misses Primary End Point in Phase 3 Trial for Niemann-Pick Disease Type C Isabella Ciccone, MPH

Findings from the phase 3 TransportNPC study showed that Trappsol Cyclo missed the primary end point in Niemann-Pick type C, but subgroup and survival data support planned 2026 NDA.

NeurologyLive® Friday 5 — October 2, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.

Todays Updates

Trappsol Cyclo Misses Primary End Point in Phase 3 Trial for Niemann-Pick Disease Type C Isabella Ciccone, MPH

Findings from the phase 3 TransportNPC study showed that Trappsol Cyclo missed the primary end point in Niemann-Pick type C, but subgroup and survival data support planned 2026 NDA.

NeurologyLive® Friday 5 — October 2, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.

Latest News

Authors discuss how best to diagnose and manage him, given the absence of any symptoms

Stay updated with the latest healthcare breakthroughs, including new phase 2 obesity data, FDA actions, and new hematology guidelines in this week’s essential news roundup.

FDA News Recap: Novel Drug Approvals in First Half of 2026

The HCPFive: Top News for Healthcare Providers from the Week of 04/05

Tepezza OBI Achieves Proptosis Reduction in Thyroid Eye Disease in Phase 3 Trial

FDA Issues Third Reproxalap CRL for Dry Eye Disease

News All Time

Consider This Before Cataract Surgery; Grant Rule: What's Next? CDC Nominee Grilled

MedPage Today reporters offer further insights into recently covered topics

New Agents for AMD Preserve Vision, Dramatically Reduce Treatment Burden

Bispecific antibody fares well against faricimab, two gene therapies extend treatment intervals

Vision Benefits in GA With Complement Inhibitor, Regardless of AMD, Anti-VEGF

Largest effects seen in eyes with GA and AMD, dual treatment with pegcetacoplan, VEGF inhibitor

Anti-VEGF Continuous Delivery Device Preserves Vision, Retinal Anatomy in DME

Similar results in patients who had port delivery system for 4 years or switched after 64 weeks

Dramatic Results Seen With Gene Therapy for Age-Related Macular Degeneration

Stable vision and retinal anatomy for up to 5 years, no supplemental therapy for up to 2 years

Drugs for Dry AMD Linked to Thickening of Retinal Nerve

More questions than answers, including whether the thickening is neuroprotective or pathologic

Stem Cell Therapy for GA Shows Early Evidence of Vision Gains, Retina Preservation

ASP7317 may offer potential to improve vision and repair retina, not just slow down atrophy

Branded Bevacizumab Approved for Wet AMD

Approval follows 20 years of off-label use of compounded formulations of the VEGF inhibitor

Use of PDE5 Inhibitor Tied to Increased Glaucoma Risk

Findings add to existing evidence linking the drug class to ophthalmic conditions

Medicare's Paying Less for Cataract Surgery. Ophthalmologists Are Turning to Lasers.

— Doctors typically charge $1,000 to $3,000 per eye for use of the laser

Medicare Is Paying Less for Cataract Surgery

Medicare pays doctors about $520 for a standard cataract procedure, down about 20% in the past decade.

EyePoint's Drug for Age-related Eye Disease Fails Late-stage Trial, Shares Tank

EyePoint said its experimental drug missed the main goal in a late-stage trial as a few patients lost vision ⁠from causes unrelated to the targeted disease, sending its...

Massage Matches Clinic Probing for Infant Tear Duct Blockage

Gently massaging the tear sacs of infants with blocked tear ducts may be as effective as clinic-based probing for clearing tearing and discharge, a noninferiority trial finds.

Can Dexamethasone Drops Prevent Retinal Disease in Preemies?

Dexamethasone eye drops administered in premature infants with early-stage retinal disease appear to reduce the odds of progression to treatment-requiring disease.

Urinary Drug Tadalafil Linked to Glaucoma Risk

Men taking tadalafil for lower urinary tract symptoms face a 22% higher risk of developing glaucoma than those who do not take the drug, a new study finds.

Study Links Uveitis to Higher Risk for Psychiatric Illness

Noninfectious uveitis is linked to higher rates of psychiatric comorbidities, with Black patients most affected, a new study finds.

Recommended News For You

ALK Inhibitor Shows Promise in Rare, Progressive Tumor Types

Race, Geography Linked to Gaps in Prostate Cancer Care

Novel probes to label macrophages associated with cancer progression using a selective dye

Imetelstat for MDS-relateret anemia er godkendt af Food and Drug Administrations panel.

Revolutionary Cancer Tx Could Transform Autoimmune Disease

Time to Rethink Maintenance Pemetrexed in NSCLC?

Long-term study links chronic conditions in midlife to higher cancer risk and mortality

Recommended Articles For You

Exploring the Latest Advances in Hodgkin's Lymphoma Treatment 

Circulating Tumor DNA Dynamics for Therapy Matching: A Comprehensive Clinical Review 

Quality of Life Through Personalized Survivorship Navigation After Multimodal Cancer Therapy 

Screening for Early Changes in Blood-Cell Production Capacity in Older Adults 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

TULSA Is Effective in Long-Term Prostate Cancer Control.

2.

AVD Chemo Regimen Shows Promise in Older Patients With HL

3.

Perioperative Nivolumab Boosts EFS Versus Neoadjuvant-Only Nivolumab in NSCLC

4.

Injecting PD-1 Drug Directly Into Oral Precancers Shrinks Lesions

5.

New Nanoparticles Can Destroy Undruggable Cancer Proteins

1.

Programmable Cell Therapies for Selective Removal of Dysfunctional Hematopoietic Cell Populations

2.

Contemporary Insights in Oncology in the Digital Era

3.

Strategic Concepts in Hematology for Modern Medicine

4.

Ferroptosis-Modulating Therapeutics in Precision Oncology

5.

Exploring the Potential of Bendamustine in Cancer Treatment

1.

International Cancer Conference

2.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

3.

International Cancer Conference

1.

Dacomitinib Case Presentation: Baseline Treatment and Current Status

2.

Blood Clotting Disorders Explained

3.

Rates of CR/CRi and MRD Negativity in Iontuzumab-Treated Patients

4.

Chemotherapy: What to Expect

5.

Evolving Space of First-Line Treatment for Urothelial Carcinoma- Case Discussion

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot